In future studies it will be interesting to see how different mRNA targets, beyond dlp/GPC6 mitigate specific phenotypic aspects of FTD and identify additional targets across the spectrum of TDP-43 proteinopathies. This evidence concerns the gene GPC6 and proteostasis deficiencies.